TCR遺伝子改変T細胞療法 2018年：技術・パイプライン・ステークホルダー・契約の産業分析

当レポートでは、TCR改変T細胞療法市場について調査し、主なTCR-T企業、技術、製品候補、ビジネスモデル、契約および融資の機会などに関する最新情報を提供しており、TCR-Tパイプラインおよびステークホルダーの分析、TCR-T資産の価値などについてまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション・概要・背景

第3章 技術

• 概要・議論
• TCR (T細胞受容体) 標的発見のための技術
• TCR発見のための技術
• TCR遺伝子改変同種T細胞
• 安全性 & 有効性を改善する次世代技術

第4章 パイプライン

• 概要・議論
• プロファイル：MAGE-A特異性TCR-T細胞
• プロファイル：NY-ESO-1特異性TCR-T細胞
• プロファイル：AFP特異性TCR-T細胞
• プロファイル：PRAME特異性TCR-T細胞
• プロファイル：WT1特異性TCR-T細胞
• プロファイル：その他標的特異性TCR-T細胞
• プロファイル：ネオアンチゲン特異性TCR-T細胞

第5章　製造

第6章　企業

• 企業概要・議論
• TCR-T細胞の専門企業
• TCR-T 活動関連企業のプロファイル
• TCR-T 活動関連のその他の企業

第7章　事業開発・融資

• TCR-T 産業にとっての大学の役割
• TCR-T にとっての大手医薬品企業・バイオテクノロジー企業の役割
• テクノロジーインライセンス契約
• 協力合意
• 企業・資産の買収
• TCR-T 企業の財務

第8章　展望

第9章　参考資料

T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.

TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.

This report “TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals”published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).

Key questions answered:

• Which targets are chosen for developmen of TCR-Ts?

• How close are neoantigen-specific TCR-Ts to the clinic?

• Which technologies are used for generation of T-Cell Receptors?

• Has clinical proof-of-concept been shown for any TCR-T?

• How does the TCR-T pipeline look like?

• What manufacturing strategies and solutions have companies chosen?

• Are next generation TCR-Ts already in development?

• What are the key technologies for a successful TCR-T?

• Who are the key players in the TCR-T field?

• How tough is competition among TCR-T developers?

• Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?

• Which technologies and assets attract licensees?

• How is the financing situation for TCR-T?

• What are the key success factors for TCR-Ts?

Target audience:

• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analyst
• CSO's
• CEO's
• CIO's
• COO's
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

SAMPLE

Table of Contents

1. Executive Summary

2. Introduction, Overview & Background

3. Technologies

• 3.1. Overview & Discussion
  • 3.1.1. Technologies for Discovery of Antigens for TCRs
  • 3.1.2. Technologies for Discovery of TCRs
  • 3.1.3. Allogeneic T-Cell Technologies
  • 3.1.4. Technologies for Next Generation TCR T-Cells
• 3.2. Technologies for Discovery of Targets for TCRs
  • 3.2.1. XPRESIDENT
  • 3.2.2. Target Selection for SPEAR T-Cells
  • 3.2.3. Phosphopeptide Library
  • 3.2.4. HTS Platform for Neoantigen Identification
  • 3.2.5. pMHC Target Discovery
  • 3.2.6. EpiTarget Platform
  • 3.2.7. Neoantigen Prediction
• 3.3. Technologies for TCR Discovery
  • 3.3.1. SPEAR T-Cell Technology
  • 3.3.2. High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
  • 3.3.3. Single Cell Sequencing Platform
  • 3.3.4. TCR-GENErator
  • 3.3.5. HTS TCR Discovery and Sleeping-Beauty Expression System
  • 3.3.6. Natural, High Affinity TCRs (Bellicum)
  • 3.3.7. High-throughput cloning and characterisation of naturally selected TCRs
  • 3.3.8. Natural TCR Library
  • 3.3.9. Natural TCRs from Vaccinated Patients
  • 3.3.10. T-Rx Mammalian TCR Display
  • 3.3.11. VelociT for T-Cell Receptor Discovery
  • 3.3.12. Combinatorial TCR Exchange (CTE)
  • 3.3.13. Immune Repertoire Capture
  • 3.3.14. E-ALPHA Phage Display
  • 3.3.15. TCRL Antibodies
  • 3.3.16. ACTolog
  • 3.3.17. NEO-STIM
• 3.4. TCR Engineered Allogeneic T-Cells
  • 3.4.1. ACTallo
  • 3.4.2. universal Immune Cell Therapies (uICT)
  • 3.4.3. GammaDelta T-Cells
  • 3.4.4. Universal Donor Stem Cells
  • 3.4.5. ATO Allogeneic T-Cells
• 3.5. Next Generation Technologies to Improve Safety & Efficacy
  • 3.5.1. ARTEMIS Technology
  • 3.5.2. CID Technology Platform
  • 3.5.3. Custom Cell Engineering Technologies synNotch and Throttle
  • 3.5.4. DEACT Technology
  • 3.5.5. Dominant TCR Technology
  • 3.5.6. RetroNectin and siTCR Vector Technologies
  • 3.5.7. Stem-to-T-Cell Technology
  • 3.5.8. Transmembrane Immunomodulatory Protein (TIP) Technology

4. Pipeline

• 4.1. Overview & Discussion
  • 4.1.1. Proof-of-concept
  • 4.1.2. Target Selection
  • 4.1.3. T-Cell Sources & Subtypes
  • 4.1.4. Use of Switches & Next Generation Constructs
• 4.2. Profiles of MAGE-A Specific TCR T-Cells
  • 4.2.1. KITE-718
  • 4.2.2. MAGE-A4c1032 T
  • 4.2.3. MAGE-A10c796 T
  • 4.2.4. TBI-1201
• 4.3. Profiles of NY-ESO-1 Specific TCR T-Cells
  • 4.3.1. GSK3377794
  • 4.3.2. NYCE T Cells
  • 4.3.3. TBI-1301
• 4.4. Profiles of AFP Specific TCR T-Cells
  • 4.4.1. AFPc332 T
  • 4.4.2. ET1402L1 CAR T-Cells
• 4.5. Profiles of PRAME Specific TCR T-Cells
  • 4.5.1. BPX-701
  • 4.5.2. MDG1011
  • 4.5.3. Dual Switch PRAME TCR T-Cells
• 4.6. Profiles of WT1 Specitic TCR T-Cells
  • 4.6.1. CMD-602
  • 4.6.2. JTCR016
  • 4.6.3. WT1-Specific Transgenic T-Cells
• 4.7. Profiles of Other Target Specific TCR T-Cells
  • 4.7.1. IMA201
  • 4.7.2. KITE-439
  • 4.7.3. LTC-H1
  • 4.7.4. TC-210
  • 4.7.5. ZI-H04
  • 4.7.6. ZI-T01
• 4.8. Profiles of Neoantigen Specific TCR T-Cells
  • 4.8.1. IMA101
  • 4.8.2. NEO-PTC-01

5. Manufacturing

6. Companies

• 6.1. Company Overview & Discussion
  • 6.1.1. Pure Play TCR T-Cell Companies
  • 6.1.2. Diversified Companies with TCR-T Activities
• 6.2. Pure Play TCR T-Cell Companies
  • 6.2.1. Adaptimmune Therapeutics
  • 6.2.2. Gadeta
  • 6.2.3. Immatics US
  • 6.2.4. Lion TCR
  • 6.2.5. Tactiva Therapeutics
  • 6.2.6. Zelluna Immunotherapies
  • 6.2.7. TCR2 Therapeutics
• 6.3. Profiles of Diversified Companies with TCR-T Activities
  • 6.3.1. Adicet Bio
  • 6.3.2. AgenTus Therapeutics
  • 6.3.3. Bellicum Pharmaceuticals
  • 6.3.4. BioNTech
  • 6.3.5. Bluebird bio
  • 6.3.6. Cell Medica
  • 6.3.7. Eureka Therapeutics
  • 6.3.8. GlaxoSmithKline
  • 6.3.9. Intellia Therapeutics
  • 6.3.10. Juno, a Celgene Company
  • 6.3.11. Kite, a Gilead Company
  • 6.3.12. Medigene
  • 6.3.13. Neon Therapeutics
  • 6.3.14. Regeneron Pharmaceuticals
  • 6.3.15. Takara Bio
  • 6.3.16. TC BioPharm
  • 6.3.17. Tmunity Therapeutics
  • 6.3.18. ZIOPHARM Oncology
• 6.4. Other Companies with TCR-T Activities
  • 6.4.1. Alpine Immune Sciences
  • 6.4.2. Atreca
  • 6.4.3. ImmunoCellular Therapeutics

7. Business Development & Financing

• 7.1. Role of academia for the TCR-T industry
• 7.2. Role of Big Pharma & Biotech for TCR-T
• 7.3. Technology In-Licensing Deals
• 7.4. Collaborative Arrangements
• 7.5. Acquisitions of Companies and Assets
• 7.6. Financing of TCR-T Companies

8. Outlook & Perspectives

9. References

List of Tables

• Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
• Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
• Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
• Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
• Table 5: Overview of TCR T-Cell Constructs in Development
• Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
• Table 7: Overview of in-house Company Manufacturing Solutions
• Table 8: Overview of Company Choices of CMO
• Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
• Table 10: Overview of TCR T-Cell Company Profiles
• Table 11: Overview of Profiles of Pure Play TCR-T Companies
• Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
• Table 13: Adaptimmune's Pipeline of SPEAR T-Cells
• Table 14: TCR T-cell Pipeline of Lion TCR
• Table 15: TCR2 Therapeutics' TRuC-T Cell Pipeline
• Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
• Table 17: Bellicum Pharmaceuticals' Pipeline
• Table 18: Cell Medica's Pipeline
• Table 19: Overview of Kite Pharma's Access to Technologies with Focus on TCR
• Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
• Table 21: TC BioPharm's Pipeline of γδ T-cell programs
• Table 22: Clinical Pipeline of Tmunity Therapeutics
• Table 23: Technology Spin-Out from Academia
• Table 24: Deals with Major Pharma & Biotech
• Table 25: Technology In-Licensing from Pharma & Biotech
• Table 26: Collaborations & Joint Ventures
• Table 27: Acquisitions
• Table 28: Financing Sources of Pure Play TCR-T Companies
• Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities